CYCLERION - Trademark Details
Status: 732 - Third Extension - Granted
Image for trademark with serial number 88202400
Serial Number
88202400
Word Mark
CYCLERION
Status
732 - Third Extension - Granted
Status Date
2021-09-14
Filing Date
2018-11-21
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s) Typeset
Design Searches
260109, 260515, 260521 - Geometric figures, objects, humans, plants or animals forming or bordering the perimeter of a circle. Four or more triangles. Triangles that are completely or partially shaded.
Published for Opposition Date
2020-01-21
Attorney Name
Anessa Kramer
Law Office Assigned Location Code
L10
Employee Name
RUTLAND, BARBARA A
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of the wording "CYCLERION" with an incomplete circular design element comprised of 23 separate triangular shapes positioned around the letter "C".
Goods and Services
Pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds, namely, preparations that stimulate guanylate cyclases (sGC), increase the concentration of nitric oxide (NO), increase the concentration of cyclic guanosine monophosphate (cGMP), upregulate the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway, or utilize a synergistic interaction of the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway with a complementary signaling pathway; Pharmaceutical preparations, namely, pharmaceutical preparations and substances for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds
Goods and Services
Pharmaceutical research and development; conducting pharmaceutical clinical trials for others; pharmaceutical product development
Pseudo Mark
C CYCLERION
Translation of Words in Mark
The wording "CYCLERION" has no meaning in a foreign language.
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2018-12-13
Primary Code
005
Current Trademark Owners
Party Name
Cyclerion Therapeutics, Inc.
Party Type
20 - Owner at Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Cyclerion Therapeutics, Inc.
Party Type
20 - Owner at Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Cyclerion Therapeutics, Inc.
Party Type
10 - Original Applicant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Anessa Kramer
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship TypeReel Number
Continuity Child88977804
Madrid International Filings
Entry Number
1
Reference Number
A0086180
Original Filing Date USPTO
2019-05-20
International Registration Number
1477461
International Registration Date
2019-05-20
International Status Code
480
International Renewal Date
2029-05-20
Madrid History Events
DateCodeDescription
2020-06-12PDBNXDIVISION OF BASE APPLICATION PROCESSED BY IB
2019-07-18CREATAPPLICATION FOR IR REGISTERED BY IB
2020-09-30CBPCPPARTIAL CEASING OF EFFECT TO BE PROCESSED
2020-10-08CBNARCEASING OF EFFECT REVIEWED - NO ACTION REQUIRED BY OFFICE
2020-05-14DBCRPDIVISIONAL OF BASE APP NOTICE CREATED, TO BE SENT TO IB
2020-05-14DBCSPDIVISIONAL OF BASE APP NOTICE SENT TO IB
2019-05-20NEWAPNEW APPLICATION FOR IR RECEIVED
2019-05-23MCERTMANUALLY CERTIFIED
2019-05-23APPSTIR CERTIFIED AND SENT TO IB
Trademark Events
Event DateEvent Description
2018-11-24NEW APPLICATION ENTERED IN TRAM
2018-12-13NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2018-12-14NOTICE OF DESIGN SEARCH CODE E-MAILED
2018-12-18ASSIGNED TO EXAMINER
2018-12-19NON-FINAL ACTION WRITTEN
2018-12-19NON-FINAL ACTION E-MAILED
2018-12-19NOTIFICATION OF NON-FINAL ACTION E-MAILED
2019-06-19TEAS RESPONSE TO OFFICE ACTION RECEIVED
2019-06-25ASSIGNED TO LIE
2019-06-27CORRESPONDENCE RECEIVED IN LAW OFFICE
2019-06-27TEAS/EMAIL CORRESPONDENCE ENTERED
2019-07-09FINAL REFUSAL WRITTEN
2019-07-09FINAL REFUSAL E-MAILED
2019-07-09NOTIFICATION OF FINAL REFUSAL EMAILED
2019-12-16EXAMINERS AMENDMENT -WRITTEN
2019-12-16EXAMINERS AMENDMENT E-MAILED
2019-12-16NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
2019-12-16EXAMINER'S AMENDMENT ENTERED
2019-12-17APPROVED FOR PUB - PRINCIPAL REGISTER
2020-01-01NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2020-01-21PUBLISHED FOR OPPOSITION
2020-01-21OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2020-03-17NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2020-04-26TEAS REQUEST TO DIVIDE RECEIVED
2020-05-12CASE ASSIGNED TO INTENT TO USE PARALEGAL
2020-04-26DIVISIONAL REQUEST RECEIVED
2020-05-13DIVISIONAL PROCESSING COMPLETE
2020-05-14CORRECTED NOA E-MAILED
2020-05-15TEAS EXTENSION RECEIVED
2020-05-15EXTENSION 1 FILED
2020-05-15EXTENSION 1 GRANTED
2020-05-19NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2021-03-08TEAS EXTENSION RECEIVED
2021-03-08EXTENSION 2 FILED
2021-03-08EXTENSION 2 GRANTED
2021-03-10NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2021-09-14TEAS EXTENSION RECEIVED
2021-09-14EXTENSION 3 FILED
2021-09-14EXTENSION 3 GRANTED
2021-09-16NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED